Rapamycin

What the evidence says

Rapamycin inhibits mTOR, a nutrient-sensing pathway connected to growth and metabolism. Its longevity reputation rests heavily on animal work: an NIH Interventions Testing Program study extended median and maximal lifespan in genetically heterogeneous mice even when treatment began late in life. That result has not been reproduced as a human longevity outcome.^[3][1]

A 2024 systematic review identified 19 human studies of rapamycin or related rapalogs. It found improvements in selected immune, cardiovascular, and skin-related physiological parameters, but no significant overall effects in endocrine, muscular, or neurological systems and major gaps across other systems.^[1]

A placebo-controlled pilot in 25 generally healthy adults aged 70 to 95 suggested eight weeks of low-dose treatment was feasible, but it was far too small and short to establish efficacy. The 48-week PEARL trial found no change in its primary visceral-fat outcome; reported benefits came from secondary or subgroup analyses and need independent confirmation.^[2][4]

Results from related mTOR inhibitors cannot be assumed to prove rapamycin works. A large phase 3 trial of RTB101 in older adults failed its primary clinical respiratory-illness endpoint despite changing antiviral gene expression, illustrating the gap between biomarkers and patient outcomes.^[5]

Sirolimus prescribing information is for transplant immunosuppression, not preventive aging, and warns about infections, malignancy, lipid abnormalities, impaired wound healing, drug interactions, and monitoring needs. No approved prescribing framework treats rapamycin as a general anti-aging medicine.^[6]